Ideal Cures Pvt. Ltd. gains US Patent for sodium alginate based aqueous film coating technology

Ideal Cures Pvt. Ltd. receives key US Patent for sodium alginate based aqueous film coating technology

MUMBAI, India--(BUSINESS WIRE)--Ideal Cures, a company specialising in film coating compositions on tablets, pellets and granules for the pharma, health and dietary supplement industry, has secured a US patent for an innovation, claimed as both cost-effective and non-toxic.

Ideal Cures Pvt. Ltd. founded and based in Mumbai announced on March 27th receiving of US Patent Number 8,123,849, relating to aqueous film coating composition based on sodium alginate for application in pharmaceutical and Nutraceutical - tablets, caplets, pellets and granules. Inventive composition provides elegant glossy prompt release coating which does not retard release of active ingredient from the coated substrate. This is the first time an Indian pharmaceutical excipient manufacturing company has been granted US patent on ready-to-use film coating composition.

This raises Ideal Cures patent portfolio to Ten granted patents which includes Nine granted patents in India. Ideal cures also own a variety of intellectual property for film coating composition in pharmaceutical and Nutraceutical industry for Immediate and Delayed release technologies.

The patent covers the technology of a coating composition comprising sodium alginate with 20% Recon level, which will result in saving of upto 40% coating time for pharmaceutical and Nutraceutical industry as compared to compositions based on Hydroxy-Propyl-Methyl-Cellulose.

The technology will provide an excellent opportunity to pharmaceutical and Nutraceuticals industry worldwide to get rid of organic solvents like IPA and Methylene chloride which are toxic to environment and coating operators. This technology will protect tablets from moisture, sunlight, and other atmospheric conditions. Technology would also be a great help for Nutraceutical industry looking for use of Gras Status products in their formulation. Addition of colors in the composition will have a distinct advantage of creating brand identification for the user as well as smoothness in the finish would be helpful for easy passage of tablets in esophagus more particularly for bigger tablets.

The company has also filed a patent application based on a Sodium Alginate for a programmed timed release of active ingredients with pre-determined lag period. This is highly useful to active ingredients which are sensitive to acidic pH and degradation in stomach.

Speaking at a Novel Drug Delivery Symposium to bunch of scientists in Ideal Cures Lab Mr. Suresh Pareek (Managing Director and one of the Inventor) emphasized that '849 technology will provide an excellent opportunity to Nutraceuticals industry to comply with the gras status film coating systems worldwide. While the others have been struggling to develop a coating composition based on Natural Polymer which will qualify for Gras Status, we are bringing tomorrow's technology today. It definitely moves the bar ahead for the competition and will likely cause them to go back to the labs again.

This proves Ideal Cures commitment towards improvement in development of world class coating compositions, thereby improving standards of health care industry products.

Ideal Cures is an Indian company with international presence in more than 40 countries having it's subsidiary company Ideal Cures Europe SRL, Europe and has three cGMP manufacturing plants. Ideal Cures Pvt. Ltd. is perceived as major alternate supplier for the film coating system by many multinational companies, which offers them superior technical services and support with competitive product prices. Ideal Cures has reputation of meeting quality requirement at par of pharmaceutical industry and regulatory bodies. Ideal Cures has spent a decade in its relentless pursuit of excellence in finding tailor-made excipients and coating solutions for solid dosage forms. From ready to use Film Coating Systems, Modified release Technologies, NDDS and Acrylic Pharma Polymers to Extended Cooling Boosters and Neutral Spheres.

Press Release by Mr. Suresh Pareek managing Director Ideal Cures Pvt Ltd., Mumbai, India

This information was brought to you by Cision http://www.cisionwire.com
 

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.